1. Home
  2. NEPH vs PRLD Comparison

NEPH vs PRLD Comparison

Compare NEPH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$5.24

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$1.48

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEPH
PRLD
Founded
1997
2016
Country
United States
United States
Employees
31
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.0M
69.1M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
NEPH
PRLD
Price
$5.24
$1.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$4.00
AVG Volume (30 Days)
77.9K
514.2K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$17,930,000.00
$10,500,000.00
Revenue This Year
$33.32
N/A
Revenue Next Year
$12.27
N/A
P/E Ratio
$40.69
N/A
Revenue Growth
32.36
250.00
52 Week Low
$1.39
$0.61
52 Week High
$6.42
$4.22

Technical Indicators

Market Signals
Indicator
NEPH
PRLD
Relative Strength Index (RSI) 49.96 48.48
Support Level $5.06 $1.30
Resistance Level $5.97 $1.56
Average True Range (ATR) 0.59 0.16
MACD 0.04 -0.02
Stochastic Oscillator 34.90 40.23

Price Performance

Historical Comparison
NEPH
PRLD

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: